ADMS News and Press, Adamas Pharmaceuticals Inc. From 08/08/19

- Second quarter GOCOVRI® product sales of $12.7 million; total prescriptions grew to approximately 6,160 - INROADS Phase 3 study of ADS-5102 (GOCOVRI) for walking impairment in patients with multiple sclerosis (MS) enrollment completed, with topline results expected late Q4 2019...

EMERYVILLE, Calif., July 23, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2019 second quarter financial results on Thursday, August 8, 2019, after market close. Subsequently, Adamas’ management team will host a conf...

EMERYVILLE, Calif., June 18, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today announced a retrospective data analysis from pooled Phase 3 tria...

EMERYVILLE, Calif., June 03, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today announced that Gregory T. Went, Ph.D., the Company’s Founder, C...

EMERYVILLE, Calif., May 30, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today announced that Vijay Shreedhar, PhD, has joined the Company as it...

I have been following Adamas Pharmaceuticals ( ADMS ) ever since they were able to receive FDA approval for their flagship product GOCOVRI for PD dyskinesia and OFF. Since then, I have started writing for Seeking Alpha and decided to write about my Adamas journey. Most of my writing has been f...

EMERYVILLE, Calif., May 13, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today announced that Gregory T. Went, Ph.D., the Company’s Founder, Ch...

Adamas Pharmaceuticals, Inc. (ADMS) Q1 2019 Earnings Conference Call May 09, 2019, 16:30 ET Company Participants Peter Vozzo - Westwicke Partners Gregory Went - Co-Founder, Chairman & CEO Alfred Merriweather - CFO Rajiv Patni - Chief Medical Officer Conference Call Parti...

Adamas Pharma (NASDAQ: ADMS ): Q1 GAAP EPS of -$1.08 beats by $0.06 . Revenue of $11.7M (+358.8% Y/Y) misses by $0.48M . Shares -6% . Press Release More news on: Adamas Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,

- First quarter net product sales of $11.7 million - GOCOVRI® total prescriptions grew to approximately 5,820 in Q1 2019 - Phase 3 study of ADS-5102 (GOCOVRI) in walking impairment in patients with multiple sclerosis on course to complete in Q4 2019 EMERYVILLE, Calif., May...